Dec 16, 2019
PDL BioPharma Board of Directors Increases Share and Note Repurchase Authorization to $275 Million
Dec 13, 2019
PDL BioPharma to Exchange Approximately 80% of Convertible Notes Due 2021 and 2024
Dec 03, 2019
PDL BioPharma Congratulates Evofem Biosciences on Achieving Major Regulatory and Clinical Milestones with its Lead Product Candidate Amphora®
Nov 14, 2019
PDL BioPharma Reaffirms Commitment To Shareholder Value Creation
Nov 06, 2019
PDL BioPharma Reports 2019 Third Quarter Financial Results
Oct 30, 2019
PDL BioPharma to Announce Third Quarter 2019 Financial Results on November 6, 2019
Oct 24, 2019
PDL BioPharma Responds to Letter from Engine Capital
Sep 26, 2019
PDL BioPharma to Participate in the 2019 Cantor Fitzgerald Global Healthcare Conference
Aug 07, 2019
PDL BioPharma Reports 2019 Second Quarter Financial Results
Jul 31, 2019
PDL BioPharma to Announce Second Quarter 2019 Financial Results on August 7, 2019
Jun 25, 2019
PDL BioPharma Announces Departure of CFO
Jun 24, 2019
Natasha A. Hernday Elected to PDL BioPharma's Board of Directors
Jun 10, 2019
Evofem Biosciences Closes $80 Million Financing Transaction with PDL BioPharma and Other Long-time Investors
May 02, 2019
PDL BioPharma to Announce First Quarter 2019 Financial Results on May 9, 2019
Apr 16, 2019
PDL BioPharma to Hold Annual Meeting of Stockholders on June 20, 2019
Apr 11, 2019
PDL BioPharma Announces Equity Investment in Evofem Biosciences
Mar 14, 2019
PDL BioPharma Reports 2018 Fourth Quarter and Full Year Financial Results
Mar 12, 2019
PDL BioPharma to Participate at 31st Annual Roth Conference
Mar 04, 2019
PDL BioPharma Announces Launch of an Authorized Generic of Tekturna® (aliskiren) in Partnership with Prasco Laboratories
Nov 19, 2018
PDL BioPharma to Present at the 30th Annual Piper Jaffray Healthcare Conference